Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Povorcitinib (INCB054707) for moderate-to-severe hidradenitis suppurativa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Povorcitinib (povorcitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Hidradenitis Suppurativa (HS) | Phase 3 | Status: COMPLETED